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The mechanism of IP,-induced activation of saponin-permeabilised platelets has been examined. Saponin 
permeabilisation resulted in the leakage of law-M, substances into and from the cells without loss of cyto- 
plasmic proteins. Addition of IP, rapidly induced a dose-related formation of thromboxane B, and release 
into the medium, Ieading to the responses of shape change, aggregation and [W]SHT release. These re- 
sponses were inhibited by the thromboxane A, receptor antagonist AH23848. The IPzinduced release of 
45Ca from intracellular stares was not affected by indomethacin. Synthesis af thromboxane was inhibited 
if Ca2+ elevation was prevented by using Ca-EGTA buffers during permeabilisation. These studies indicate 
that IF,-induced activation was due to Ca** mobilisation leading to phospholipase activation and throm- 
boxane synthesis. 
Permeabilized platelet; Xnositof 1,4,~-trispho~hate; CaZ+ mobilization; Thromboxane synthesis 
1. rNT~UDUCT~UN 
Inositol 1,4,Strisphosphate has now been iden- 
tified as an important intracellular second 
messenger molecule that can effect the release of 
Ca” from intracellular stores in a wide variety of 
tissues fl]. In some tissues this ability of IPs to 
raise the cytosolic [Ca”] has been correlated with 
functional events, e.g. exocytosis of cortical 
granules in sea urchin eggs [2] and voltage 
responses in photoreceptor cells of Limufus [3,4]. 
It has also been shown to release Ca’” from 
platelet intracellular membranes f5-71 and more 
recently we have demonstrated that IP3 can initiate 
certain functions such as shape change, aggrega- 
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tion and release of granule-stured [‘4C]SHT when 
added to saponin-~ermeabiIised platelets [S]. 
These properties are comparable to those initiated 
by conventional agonists applied to intact 
platelets. By using inhibitors of cyclooxygenase 
and thromboxane receptor antagonists we also 
demonstrated [S] that these IP3-induced responses 
are dependent upon the formation of thromboxane 
and its Tapid release and binding to surface recep- 
tors an the platelets, These findings led us to sug- 
gest that IP3-induced release of Ca2+ from an 
intracellular membrane storage site (the platelet 
endopfasmic reticulum-like complex) is followed 
by activation of phospholipase At, release of 
arachidonic acid and the formation of thrombox- 
ane AZ by cyclooxygenase and thromboxane syn- 
thase. All these enzymes have been shown to be 
located in the same intracellular membranes which 
have the capacity to sequester Ca” through the ac- 
tion of a (Ca” + Mg’+)-ATPase [P-13]. 
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Here, our studies using saponin-permeabilised 
platelets have been extended to confirm that IP3 
triggers prostanoid synthesis through Ca2* 
mobilisation rather than by any direct effect upon 
the synthetic ‘enzymes’ involved. 
2. EXPERIMENTAL 
AH23848 was a gift from Glaxo Group 
Research, Ware, Herts. 45Ca was obtained from 
NEN (4-50 Ci/g Ca). All other reagents and 
chemicals were from sources described earlier [S]. 
2.2. Preparation of washed platelet suspensions 
Preparation of washed human platelets and 
labelling of the dense granule constituents with 
[14C]5HT were carried out as in [S], except hat the 
final resuspension buffer was of the following 
composition: 1 mM glucose, 140 mM KCI, 1 mM 
MgCl2, 0.42 mM NaH2P04, 6 mM NaHCOs and 
10 mM Hepes (pH 7.4) made up in Analar water 
(BDH) at a cell concentration of 2.5 x 10’ 
cells/ml. This platelet suspension was kept at 
37”C, gassed with 02/CO2 (95%/5%) every 
30 min and experiments were completed within 4 h 
of blood donation. Only donors who were certain 
that they had taken no aspirin-containing 
medicaments during the previous 10 days were 
used. 
2.3. ~ap~ni~ p~rmeab~~is~tion and aggregation 
experiments 
Unless otherwise indicated the following ex- 
perimental protocol was carried out at 37°C using 
a Payton 300B dual-channel aggregometer. 
Typically, 400 ~1 platelet suspension was equili- 
brated in aggregation cuvettes for 3 min and 
saponin was added at a final concentration of be- 
tween 12 and 14pg/ml. After 2 min either IP3 or 
the different agonists were added and reactions 
were followed for another 4 min. in the [i4C].5HT- 
release experiments 2pM imipramine was also 
added 2 min before saponinisation. Reactions 
were terminated by the addition of 500~1 of 3% 
glutaraldehyde, 6 mM EDTA, 150 mM KC1 (pH 
7.4). The [14C]5HT released into the supernatant 
was determined by liquid scintillation counting 
after centrifugation at 12000 x g for 3 min. 
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2.4. Measurement of thromboxane BZ in media 
These were duplicate experiments carried out in 
parallel to those with platelets not prelabelled with 
any isotopes. For these studies reactions were ter- 
minated in the aggregation cuvettes by the addition 
of 10 mM EDTA and 10pM indomethacin. After 
centrifugation at 12000 x g for 3 min the super- 
natants were assayed for thromboxane BZ (TXB2) 
by radioimmunoassay [ 14] after separation of non- 
polar materials on a Sep-Pak column. 
2.5. 4sCd+ labelling and release studies 
45Ca labelling of intact platelets was carried out 
using buffers modified to increase uptake of 45Ca 
as used by Steiner and Tateishi [ 1.5 ] and Brass [ 161. 
Platelets were isolated from PRP as described 
above and resuspended in buffer of composition 
140 mM KCl, I mM MgC12, 1 mM glucose, 
0.42 mM NaH2P04, 11.9 mM NaHCO3, 10 mM 
Pipes (pH 6.5) containing 1 mg/ml BSA and 
100 nM PGEi. The cells were incubated for 4 h at 
room temperature in the presence of 2 &i/ml 45Ca 
(4-50 Ci/gCa) and 20 FM cold CaCl2. At the end 
of this incubation period the cells were sedimented 
at 500 x g for 20 min and washed in a medium 
containing 120 mM KCI, 5 mM MgCh, 10 mM 
Pipes, 5 mM EGTA, 100 nM PGEi adjusted to pH 
6.5, centrifuged at 1000 x g for 15 min and 
resuspended in the nominally Ca’+-free KC1 
medium used for the aggregation studies at 2.5 x 
lo8 cells/ml. The uptake of 45Ca and its efflux 
from the cells followed very similar kinetics (not 
shown) to those described by Brass 1161. The 45Ca 
distributed between the cytosolic and intracellular 
pools. However, after labelling, the cytosolic pool 
quickly reached equilibrium with the external en- 
vironment (t,/, -17 min) whilst the intracellular 
storage pool loses Ca2+ much more slowly (ti/, 
-313 min). Experiments on IPS-induced release of 
45Ca were carried out between 30 and 90 min after 
final resuspension of the cells when there had been 
only a slight decrease in the 45Ca associated with 
the cells as measured by rapid filtration through 
0.45 pm Millipore membrane filters. Reaction con- 
ditions were similar to those used in the aggrega- 
tion experiments. The 400 ,LLI aliquots of platelet 
suspensions were incubated in the presence of 
14pg/ml saponin at room temperature and after 
2 min exposure to the detergent, IP3 or other 
Ca2+-mobilising agents were added and the reac- 
Volume 213, number 1 FEBS LETTERS March 1987 
tions terminated at set times by rapid filtration 
through 0.45 pm Millipore filters. The filters were 
washed twice with 10 ml of a buffer containing 
120 mM KCl, 5 mM MgClz, 10 mM Pipes, 5 mM 
EGTA (pH 7.4), air dried, and the radioactivity re- 
maining on the filter counted by liquid scintillation 
counting. 
3. RESULTS 
Addition of IP3 (1-15 PM) to washed human 
platelets permeabilised by saponin treatment 
rapidly induced shape change, aggregation and 
dense granule release [8]. These effects with IP3 
were only observed with permeabilised cells and 
are not seen with intact cells. They were also not 
observed with inositol 1,6bisphosphate (IPz). 
Under these conditions 15 FM IP3 produced shape 
change and aggregation profiles comparable to 
those produced by 0.1 U/ml thrombin and ap- 
prox. 50% of the previously incorporated 
[14C]5HT was released. The relationship between 
IP3 concentration added and thromboxane pro- 
duced has been examined and fig. la shows the for- 
mation and release of immunoreactive TXBz 
measured in the supernatants, 4 min after the addi- 
tion of varying amounts of IP3 to platelets 
permeabilised with 14 pg/ml saponin. This figure 
shows a dose-related increase in the formation of 
TXB2 from 5.4 -+ 2.8 ng TXBJml (basal levels, n 
= 6) to approx. 140 ng TXBz/ml in the presence of 
15 PM or greater amounts of IP3. The addition of 
0.1 U/ml thrombin to saponised platelets pro- 
duced 225 + 34 ng TXBJml (n = 3). Fig.lb shows 
a time curve of thromboxane release into the 
medium over 4 min; 30% of the total released ap- 
pears in 15 s and around 70% in 30 s. In this con- 
text IP3-induced shape changes are generally seen 
within 15 s of adding IP3 to the permeabilised 
platelets. 
To complement our earlier studies where we 
showed that IP3-induced platelet functions were 
totally inhibited by pretreating the platelets at the 
whole cell level with TXA2 receptor antagonists 
EP092 and EP045 before saponisation, we have 
investigated the effect of another TXA2 receptor- 
blocking agent AH23848. This compound has been 
shown to antagonise platelet responses induced by 
U46619, TXA2 and PGH2 as also activation by col- 
lagen and arachidonate [ 171. In the present studies, 
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Fig.1. (a) IPX-induced TXBz formation in saponin- 
permeabilised platelets. Washed human platelets were 
incubated in aggregation cuvettes at 37’C (400 ~1, 2.5 x 
lo8 cells/ml). Saponin was added at 14pg/ml and 
followed after 2 min by various concentrations of IP, 
(O-40pM). The reactions were stopped by 1OpM 
indomethacin and 10 mM EDTA after 6 min and 
following centrifugation the TXBZ present in the 
supernatant was assayed as described in section 2. Points 
represent mean + SE (n = 3) or mean of duplicates. 
Similar results were obtained in 3 different preparations. 
(b) IP3-induced formation of TXBl as a function of 
time. Reaction conditions are similar to those in (a). The 
concentration of IP3 used was 15 ,uM. Points represent 
mean of duplicate observations with similar results 
obtained in 2 other preparations. 
AH23848 was extremely effective in inhibiting the 
IP3-induced responses and fig.2 shows a typical ag- 
gregation trace where AH23848 was added to in- 
tact cells 2 min before saponin. The suppression of 
97 
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Fig.2. Inhibition of IPs-induced platelet responses by 
AH23848. Reaction conditions are similar to those in 
fig.la except that platelets were prelabelled with 
[14C]5HT. The agent AH23848 (30 nM) or carrier 
vehicle (NaHCO3, 0.1%) was added 3 min before 
saponin, and 15 pM IPs added 2 min after saponin. 
Figures in parentheses indicate % [14C]5HT release. 
Traces are representative of at least 7 different platelet 
preparations. 
IPs-induced aggregation was dose-dependent over 
the range 3-30 nM AH23848 with total inhibition 
at concentrations of 30 nM and over. It was 
noticeable, however, that at concentrations of the 
drug in excess of 30 nM, weak shape change 
responses were observed, but even at IO-fold 
higher concentrations (300 nM) these were not ac- 
companied by either aggregation or 5HT release. A 
second equal aliquot of AH23848 (300 nM) to in- 
tact cells added 3 min after the first addition of the 
drug did not produce shape change, probably in- 
dicating that all of the receptor sites had been oc- 
cupied by the first addition and that the shape 
change effect was not due to a non-specific 
detergent action of the drug. The weak shape 
change effect was also inhibited by the previously 
used TXA2 receptor antagonist EP092 (2 5 nM) if 
added 3 min prior to AH23848 (300 nM). Partial 
agonist activity of AH23848 has also been reported 
with some isolated smooth muscle preparations 
1171. 
To explore further our concept that the IP3 in- 
duced functional responses operate through Ca2+ 
mobilisation and thromboxane production, 
Ca/EGTA buffers were included in the suspension 
media during saponisation. Permeabilisation was 
carried out in the presence of 80 nM free Ca2+ 
(Ca/EGTA ratio of 0.5 with EGTA final concen- 
tration 1 .O mM, pH 7.4; see [18]). The Ca/EGTA 
buffer rapidly equilibrates with the cytosol when 
the plasma membrane is permeabilised by saponin 
and under these conditions concentrations of IPs 
(up to 40,uM) failed to elicit shape change, ag- 
gregation and 5HT release was reduced to basal 
levels (16.4% + 2.4, n = 3). Additionally with 
40 /rM IPs, thromboxane production (measured as 
TXB2) was inhibited by 92% [12.0 + 1.3 ng/ml n 
= 3) compared with 140 + 23 ng/ml (n = 3) in t h e 
absence of EGTA buffer], i.e. rose little above the 
basal level, suggesting that any increase in 
cytosolic [Ca2’] was prevented by the presence of 
the EGTA and no significant activation of 
phospholipase A2 takes place. 
The addition of exogenous Ca2+ (20-5OOpM 
without EGTA) also activates saponin-perme- 
abilised platelets in a dose-dependent manner giv- 
ing similar responses to that produced by IPs. In 
seven different platelet preparations 500 PM Ca2+ 
added 2 min after saponin caused shape change, 
aggregation and the release of between 47 and 67% 
of previously incorporated [14C]5HT (54.4% f 
8.2, n = 7). As with the IP3-induced responses, 
Ca’+-induced responses were similarly inhibited by 
indomethacin and thromboxane receptor an- 
tagonists. 
To demonstrate clearly that IP3 induces Ca2+ 
release from intracellular stores, intact platelets 
were first pre-incubated with 45Ca for 4 h (as 
described in section 2). The platelets were then 
washed in the EGTA-containing medium to 
remove any surface-associated cations and 
resuspended in the nominally Ca’+-free medium 
used in aggregation experiments. In such uptake 
experiments the 4sCa distributes between the 
cytosol and the intracellular membrane stores with 
perhaps a small amount in the granule pool [ 161. 
The cells were then permeabilised as before with 
14,ug/ml saponin. The loss of 45Ca through 
permeabilisation amounted to approx. 3% of the 
total cell 45Ca after 6 min incubation. However, if 
IP3 is added to the cell suspension 2 min after 
saponisation, release of 45Ca is measurable at 30 s, 
and 20% of the cell associated 45Ca is released 
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Fig.3. IPj-induced release of 4’Ca from saponin-treated 
platelets. Intact platelets were labelled with 4sCa and 
washed as described in section 2. Aliquots of platelet 
suspensions were incubated with saponin for various 
times up to 6 min (o--o). Reactions were terminated 
by rapid filtration through 0.45 ,urn filters and the 
radioactivity of the cells on the filter counted by liquid 
scintillation. IPs (15 PM) was added at 2 min (A---A) 
and reactions terminated as before. 100% 45Ca 
represents 8305 cpm/lO* cells. Points represent mean f 
SE of triplicate determinations. 
after 4 min (fig.3). This IPS-induced release is 
believed to have its origin in an internal store. This 
Ca*+ release is dose-related over the range 
0.1-15 ,uM IP3 and in control experiments with IP3 
added to intact cells no release of 45Ca was 
detected. Indomethacin (10 PM), a reversible 
cyclooxygenase inhibitor, did not inhibit the 
IP3-induced release of 4’Ca from the permeabilised 
cells. In fact (as shown in table 1) the presence of 
indomethacin resulted in a consistent but barely 
significant increase (-4010) in 45Ca released, above 
the levels recorded for IP3 in the absence of in- 
domethacin. Table 1 also shows that the 
IP3-induced release of 4’Ca is unaffected by the 
presence of 80 nM free Ca*+ (Ca/EGTA buffer) in 
the external medium which of course equilibrates 
with the cytosol compartment in the permeabilised 
platelet. Additionally, the mitochondrial inhibitors 
antimycin (10pM) and oligomycin (5 PM) were 
also without effect upon the release of 45Ca sug- 
gesting that the stimulated release took place from 
a non-mitochondrial compartment and probably 
the endoplasmic reticulum-like membrane com- 
plex. Both thrombin (0.2 U/ml) and the Ca*+ 
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Table 1 
Release of 45Ca from saponin-permeabilised platelets 
Experimental 
conditions 
4sCa associated ‘70 
with the platelets release 
after filtration 
and washing 
Control cells 
Cells + saponin 
5931 f 51 (loo) - 
(I4 &ml) 5778 f 106 (97.0) 3.0 
Cells + saponin + IPs 
(15 PM) 5020 f 311 (84.6) 15.4 
Cells + saponin + IP3 + 
indo (10 PM) 4736 + 52 (79.8) 20.2 
Cells + saponin + IP3 + 
80 nM Ca-free 
Cells + saponin + 
4863 f 77 (82.0) 18.0 
A23187 (5 /IM) 
Cells + saponin + 
3182 f 281 (53.6) 46.4 
thrombin (0.2 U/ml) 3071 f 462 (51.7) 48.3 
Saponin was added at zero time. IPs, thrombin or 
A23 187 was added 2 min after saponin and the reactions 
stopped at 6 min by rapid filtration through a 0.45 p 
filter. Figures in parentheses refer to % associated with 
cells. Data are means + SD (n = 3). indo, indomethacin 
ionophore A23 187 (5 PM) released 45Ca from a se- 
questered site with Vo release values of 46% and 
48% respectively of the total cell associated 45Ca. 
4. DISCUSSION 
The ability of IP3 to mobilise Ca*+ from an in- 
tracellular storage site in blood platelets has been 
further substantiated in this present study. Using 
saponin-permeabilised human platelets, we have 
also identified (by the end product TXB2) the ma- 
jor intracellular enzyme sequence that is activated 
immediately following IPs mobilisation of Ca*+. 
This enzyme sequence is initiated by Ca*+ stimula- 
tion of phospholipase A2 which results in the 
liberation of arachidonic acid. The fatty acid is 
rapidly converted to thromboxanes by the cycloox- 
ygenase and thromboxane synthase, both of which 
are resident in the same intracellular membrane 
complex from which the Ca*+ is released by the 
IP3. Release of TXAz from the cell mediates func- 
tional responses through binding to specific sur- 
face membrane receptors. The use of the 
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thromboxane receptor antagonist AH23848, ap- 
plied at the intact cell level before permeabilisa- 
tion, totally inhibited the IP3-induced aggregation 
and release phenomena. This further emphasises 
the importance of thromboxane receptor occupan- 
cy in the full expression of these platelet proper- 
ties. Release of arachidonic acid from 
diacylglycerol is not considered to be a 
Ca*+-requiring process and in fact earlier observa- 
tions from this laboratory indicated that 
diacylglycerol lipase activities (both the low-K, 
and high-&, forms of the enzyme) are substantial- 
ly activated in the presence of EGTA and partially 
inhibited by elevated Ca”’ levels [ 19,201. From our 
previous studies with saponin-permeabilised 
platelets and the present data, the amount of se- 
questered Ca2+ released by IP3 appears to be suffi- 
cient to activate phospholipase-A2 without the 
need for influx of external Ca2+ from the plasmatic 
environment. In the saponin-permeabilised platelet 
model using analytical grade water for all the 
reagents and no EGTA present, the environmental 
[Ca2’] is usually less than 3 x 10e6 M. This 
equilibrates with the platelet cytosol through the 
detergent-induced channels and it is the incremen- 
tal change above this basal level, contributed to by 
IP3 release of Cat+ from an intracellular non- 
mitochondrial store, that triggers the liberation of 
the precursor arachidonic acid from membrane 
phospholipids. The minimal amount of TXAz 
believed to be required to produce platelet activa- 
tion in aggregometry studies is generally thought to 
be around 25 ng/ml[21]. This amount is generated 
in a few seconds with 10 pM IP3 and levels of IP3 
- 25 ccM lead rapidly to TXB;! concentrations in 
the external media over 100 ng/ml. 
It should be noted, however, that in the present 
study less TXAz is produced by direct entry of IP3 
into the permeabilised platelet han when thrombin 
is used as the stimulus (140 and 220 nglml, respec- 
tively). Similarly IPj at optimum concentrations 
releases about 40-50% of the internally se- 
questered 4SCa pool which can be released by 
0.2 U/ml thrombin. One possible explanation for 
this is that in by-passing phospholipase C involve- 
ment initially, through the direct entry of IP3 into 
the cytosol, other intracellular events initiated by 
thrombin receptor occupancy are not brought into 
interplay. 
Two earlier reports presented the possibility that 
100 
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IP3 may also have a direct effect on certain en- 
zymes since it was shown that it stimulated protein 
kinases in brain cell lysates [22] and similarly in 
permeabilised platelets [23]. However, subsequent 
reports by both groups [24,25] indicated that the 
resulting phosphorylations observed in the earlier 
experiments from brain were not reproducible and 
in the latter case with platelets were due to secon- 
dary formation of TXA2. It therefore appears that 
IP3 acts predominantly, if not solely, through Ca”’ 
mobilisation from an internal store. 
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